Investment Rating - The investment rating for the company is "Buy" and is maintained [8]. Core Views - The company's performance meets expectations, with a turning point observed in domestic performance. In 2024, the company achieved revenue of 10.3 billion yuan, a year-on-year decrease of 9.73%. The net profit attributable to the parent company was 1.262 billion yuan, down 36.08% year-on-year. However, in Q1 2025, the company reported revenue of 2.478 billion yuan, a year-on-year increase of 5.42%, indicating a recovery trend [5][10]. - The company is deepening its globalization strategy, achieving overseas revenue of 2.266 billion yuan in 2024, a year-on-year increase of 35.07%. The company has expanded its overseas business to over 85 countries and regions, with significant market penetration in North America and Europe [10][11]. - The company is focusing on research and innovation, with R&D investment of 2.261 billion yuan in 2024, accounting for 21.95% of revenue. The company has launched several strategic innovative products and is a leader in AI-enabled imaging devices [10][11]. Summary by Sections Financial Performance - In 2024, the company achieved total revenue of 10.3 billion yuan, with a decline in sales of medical imaging and radiation therapy equipment by 14.93% to 8.445 billion yuan. The domestic revenue was 7.664 billion yuan, down 19.43% year-on-year. However, Q4 2024 showed improvement in domestic bidding data, and Q1 2025 revenue growth indicates a recovery [10][11]. - The company expects net profits for 2025-2027 to be 2.0 billion, 2.5 billion, and 3.15 billion yuan respectively, with corresponding PE ratios of 55X, 44X, and 35X [10][11]. Global Expansion - The company has made significant strides in its global strategy, with a focus on high-end markets and emerging regions. It has established local sales in key markets such as the Netherlands, France, and Italy, and has covered over 70% of the U.S. state-level administrative regions [10][11]. Research and Development - The company is advancing its R&D efforts, with a focus on the entire supply chain from core components to intelligent system platforms. In 2024, it launched several innovative products and has over 20 AI-enabled devices approved, leading the industry [10][11].

Investment Rating - The report maintains an "Outperform" rating for the company with a target price of RMB 156.55, representing a potential upside of 17% from the current price of RMB 132.90 [1][9]. Core Insights - The company achieved a revenue of RMB 10.30 billion in 2024, a decrease of 9.73% year-on-year, and a net profit attributable to shareholders of RMB 1.26 billion, down 36.08% [9][10]. - In Q1 2025, the company reported a revenue of RMB 2.48 billion, an increase of 5.42%, and a net profit of RMB 370 million, up 1.87% [9][10]. - The company is expected to have EPS of RMB 2.20 in 2025 and RMB 2.65 in 2026, with a new forecast for 2027 at RMB 3.18 [9][10]. Financial Summary - Revenue and Profit Forecasts: - 2023A: Revenue of RMB 11.41 billion, Net Profit of RMB 1.97 billion - 2024A: Revenue of RMB 10.30 billion, Net Profit of RMB 1.26 billion - 2025E: Revenue of RMB 12.44 billion, Net Profit of RMB 1.81 billion - 2026E: Revenue of RMB 14.97 billion, Net Profit of RMB 2.18 billion - 2027E: Revenue of RMB 17.99 billion, Net Profit of RMB 2.62 billion [2][5]. - Key Financial Ratios: - Net Asset Return Rate (ROE) is projected to be 6.3% in 2024 and 10.2% in 2027 [2][5]. - The Price-to-Earnings (P/E) ratio is expected to be 86.80 in 2024 and decrease to 41.84 by 2027 [2][5]. Market Position and Strategy - The company continues to increase its domestic market share, with a structural growth of over 3 percentage points year-on-year, particularly in high-end products [10][11]. - In 2024, the company achieved overseas revenue of RMB 2.27 billion, a growth of 35.07%, accounting for 22% of total revenue [11][12]. - The service revenue reached RMB 1.36 billion in 2024, representing a 26.80% increase and accounting for 13.16% of total revenue [12]. Conclusion - The report highlights the company's strong position in the medical imaging equipment sector, supported by ongoing domestic policy and international market expansion, justifying the "Outperform" rating and the target price increase [9][10][11].

Investment Rating - The investment rating for the company is "Outperform the Market" [6][24][29] Core Views - The company faced performance pressure in 2024 due to delays in medical equipment bidding, but saw a recovery in Q1 2025 as the market rebounded [1][9] - The domestic market was under pressure, while the overseas market showed significant growth, with revenue increasing by 32.3% [2][14] - The company's gross margin remained stable at 48.54%, while expenses increased due to higher R&D and sales costs [3][21] Financial Performance - In 2024, the company achieved revenue of 103.00 billion yuan, a decrease of 9.73%, and a net profit of 12.62 billion yuan, down 36.08% [1][9] - For Q1 2025, revenue was 24.78 billion yuan, up 5.42%, and net profit was 3.70 billion yuan, an increase of 1.87% [1][9] - The company expects revenue for 2025-2027 to be 120.4 billion yuan, 137.7 billion yuan, and 155.3 billion yuan, with corresponding net profits of 17.0 billion yuan, 20.8 billion yuan, and 23.3 billion yuan [24][27] Product Line Analysis - In 2024, equipment sales revenue was 84.45 billion yuan, down 14.9%, with specific product lines showing varied performance [2][14] - The repair service business grew rapidly, achieving revenue of 13.56 billion yuan, an increase of 26.8% [2][14] Market Dynamics - The domestic market revenue was 76.6 billion yuan, down 21.3%, while the overseas market revenue reached 22.2 billion yuan, up 32.3%, increasing its share to 21.6% [2][14] - The company's competitive edge in the global market was enhanced by technological innovation and product diversification [2][14] Expense and Margin Analysis - The company's gross margin was stable at 48.54%, while the total expense ratio increased to 39.11% [3][21] - Sales expense ratio rose to 17.70%, management expense ratio to 5.40%, and R&D expense ratio to 17.10% [3][21]

Investment Rating - The report maintains an "Outperform" rating for the company with a target price of RMB 156.55, representing a potential upside of 17% from the current price of RMB 132.90 [1][10]. Core Insights - The company achieved a revenue of RMB 10.30 billion in 2024, a decrease of 9.73% year-on-year, with a net profit attributable to shareholders of RMB 1.26 billion, down 36.08% [5][10]. - In Q1 2025, the company reported a revenue of RMB 2.48 billion, an increase of 5.42%, and a net profit of RMB 370 million, up 1.87% [5][10]. - The company is expected to have EPS of RMB 2.20 in 2025 and RMB 2.65 in 2026, with a new forecast for 2027 at RMB 3.18 [5][10]. Domestic Market Performance - The company continues to increase its domestic market share, with a revenue of RMB 7.66 billion in 2024, reflecting a decline of 19.43% [11]. - The company achieved structural breakthroughs with a differentiated strategy, increasing overall business share by over 3 percentage points year-on-year, with high-end products contributing nearly 5 percentage points [11]. International Market Expansion - The company reported overseas revenue of RMB 2.27 billion in 2024, an increase of 35.07%, accounting for 22% of total revenue [12]. - The company has established a marketing team of over 700 and more than 1,000 service engineers, covering over 200 cities in more than 85 countries [12]. Service Revenue Growth - In 2024, service revenue reached RMB 1.36 billion, up 26.80%, accounting for 13.16% of total revenue [13]. - The after-sales service gross profit margin increased by 1.71 percentage points to 63.43%, supporting overall profitability [13].

Core Viewpoint - In 2024, the company faced performance pressure due to delays in medical equipment bidding, but a market recovery in Q1 2025 led to a year-on-year performance rebound [1][2]. Financial Performance - In 2024, the company achieved revenue of 10.3 billion yuan (-9.73%) and a net profit attributable to shareholders of 1.262 billion yuan (-36.08%) [1]. - Q4 2024 revenue was 3.346 billion yuan (-15.90%), with a net profit of 591 million yuan (-35.09%) [1]. - Q1 2025 revenue increased to 2.478 billion yuan (+5.42%), with a net profit of 370 million yuan (+1.87%) [1]. Product Line Analysis - In 2024, equipment sales revenue was 8.445 billion yuan (-14.9%), with specific product line revenues showing varied performance: CT/MR/MI/XR/RT products down by 25%/-3%/-16%/-23% but RT business grew by 18% [1]. - The maintenance service business grew rapidly, achieving revenue of 1.356 billion yuan (+26.8%) due to increased installed capacity [1]. Market Performance - Domestic market revenue in 2024 was 7.66 billion yuan (-21.3%), impacted by industry restructuring and prolonged equipment update policies [2]. - Overseas market revenue reached 2.22 billion yuan (+32.3%), with its revenue share increasing to 21.6% (+6.9 percentage points) due to technological innovation and product diversification [2]. Profitability and Expenses - The company's gross margin in 2024 was 48.54% (+0.06 percentage points), remaining stable [2]. - Expense ratios increased: sales expense ratio at 17.70% (+2.19 percentage points), management expense ratio at 5.40% (+0.48 percentage points), R&D expense ratio at 17.10% (+1.95 percentage points) [2]. Investment Outlook - The domestic bidding recovery is expected to drive performance recovery, with a significant impact from the global strategy [3]. - Revised revenue forecasts for 2025-2027 are 12.04 billion yuan, 13.77 billion yuan, and 15.53 billion yuan, with corresponding net profits of 1.70 billion yuan, 2.08 billion yuan, and 2.33 billion yuan [3].

Investment Rating - The investment rating for the company is "Buy" [4] Core Insights - The company reported a revenue of 10.3 billion yuan in 2024, a year-on-year decline of 9.73%, and a net profit of 1.262 billion yuan, down 36.09% year-on-year. However, in Q1 2025, the company achieved a revenue of 2.478 billion yuan, representing a year-on-year growth of 5.42%, and a net profit of 370 million yuan, up 1.87% year-on-year [1][2] Summary by Sections Revenue and Profitability - In 2024, the company's equipment business revenue was 8.445 billion yuan, down 14.93%, with CT revenue at 3.048 billion yuan (-25.03%) and MR revenue at 3.192 billion yuan (-2.66%). Maintenance service revenue grew by 26.80% to 1.356 billion yuan [2] - The company expects revenues for 2025-2027 to be 12.065 billion yuan, 14.333 billion yuan, and 17.098 billion yuan respectively, with net profits of 1.839 billion yuan, 2.299 billion yuan, and 2.728 billion yuan [8][10] Market Position - The company achieved a domestic revenue of 7.664 billion yuan in 2024, down 19.43%, but increased its market share by over 3 percentage points, particularly in high-end products. The overseas revenue reached 2.266 billion yuan, a growth of 35.07%, accounting for 22% of total revenue [3][4] Research and Development - In 2024, the company invested 2.261 billion yuan in R&D, representing 21.95% of its revenue. It has established a comprehensive self-research system covering core components, achieving 100% self-research capability in key parts for MR [4][7] Financial Metrics - The company reported a gross margin of 48.5% in 2024, with projections for 2025-2027 showing slight improvements in gross margin and net profit margin [10][12]

Investment Rating - The investment rating for the company is "Buy" [6] Core Views - The company's performance in 2024 faced temporary pressure due to domestic industry restructuring and equipment update cycles, while overseas markets experienced rapid growth. The first quarter of 2025 showed positive year-on-year growth in both revenue and profit, indicating a gradual release of equipment update demand. The company achieved breakthroughs in high-end markets and penetration in emerging regions, enhancing its global presence as a leading domestic medical imaging company [2][3] Financial Performance Summary - In 2024, the company reported revenue of 10.3 billion yuan, a year-on-year decline of 9.73%, and a net profit attributable to shareholders of 1.262 billion yuan, down 36.09%. The first quarter of 2025 saw revenue of 2.478 billion yuan, an increase of 5.42%, and a net profit of 370 million yuan, up 1.87% [1][5] - The service business showed strong performance in 2024, with revenue of 1.356 billion yuan, a year-on-year increase of 26.80%, and a gross margin of 63.43%. In contrast, the equipment business faced challenges, with revenue of 8.445 billion yuan, a decline of 14.93% [2][3] - The company's overseas revenue reached 2.22 billion yuan in 2024, a year-on-year increase of 33.81%, while domestic revenue was 7.664 billion yuan, down 19.43% [3] Product and Market Development - The company has launched over 140 innovative products by the end of 2024, with significant certifications including 46 CE MDR and 49 FDA approvals. Notable products include advanced MRI and CT systems, enhancing the company's product portfolio [4] - The company has expanded its overseas business to over 85 countries and regions, achieving significant market penetration in North America and Europe, and making strides in emerging markets such as India, Turkey, Mexico, and Brazil [3][4] Future Projections - Revenue projections for 2025 to 2027 are estimated at 12.354 billion yuan, 15.130 billion yuan, and 18.326 billion yuan, respectively, with year-on-year growth rates of 19.9%, 22.5%, and 21.1%. Net profit projections for the same period are 1.803 billion yuan, 2.245 billion yuan, and 2.746 billion yuan, with growth rates of 42.8%, 24.6%, and 22.3% [4][5]

Investment Rating - The investment rating for the company is "Buy" [6] Core Views - The company's performance in 2024 faced temporary pressure due to domestic industry restructuring and equipment update cycles, while overseas markets experienced rapid growth. The first quarter of 2025 showed positive year-on-year growth in both revenue and profit, indicating a gradual release of equipment update demand. The company achieved breakthroughs in high-end markets and penetration in emerging regions, enhancing its global product layout [2][3] Financial Performance Summary - In 2024, the company reported revenue of 10.3 billion yuan, a year-on-year decline of 9.73%, and a net profit of 1.262 billion yuan, down 36.09%. The first quarter of 2025 saw revenue of 2.478 billion yuan, an increase of 5.42%, and a net profit of 370 million yuan, up 1.87% [1][5] - The service business showed strong performance in 2024, with revenue of 1.356 billion yuan, a year-on-year increase of 26.80%, and a gross margin of 63.43%. In contrast, the equipment business faced challenges, with revenue of 8.445 billion yuan, a decline of 14.93% [2] - The company’s overseas revenue reached 2.220 billion yuan in 2024, a year-on-year increase of 33.81%, while domestic revenue was 7.664 billion yuan, down 19.43% [3] Product and Market Development - The company has launched over 140 innovative products by the end of 2024, with significant certifications including 46 CE MDR and 49 FDA approvals. Notable products include advanced MRI and CT systems, enhancing the product portfolio [4] - The company has expanded its overseas business to over 85 countries and regions, achieving significant market penetration in North America and Europe, and making strides in emerging markets such as India, Turkey, Mexico, and Brazil [3] Future Projections - Revenue projections for 2025-2027 are estimated at 12.354 billion yuan, 15.130 billion yuan, and 18.326 billion yuan, representing year-on-year growth rates of 19.9%, 22.5%, and 21.1% respectively. Net profit projections for the same period are 1.803 billion yuan, 2.245 billion yuan, and 2.746 billion yuan, with growth rates of 42.8%, 24.6%, and 22.3% respectively [4][5]

Core Viewpoint - The company reported a decline in revenue and net profit for 2024, but showed growth in Q1 2025, indicating a potential recovery trend in the near future [1][2]. Group 1: Financial Performance - In 2024, the company achieved operating revenue of 10.3 billion yuan, a year-on-year decrease of 9.7%, and a net profit attributable to shareholders of 1.262 billion yuan, down 36.1% year-on-year [1]. - For Q1 2025, the company reported operating revenue of 2.478 billion yuan, a year-on-year increase of 5.4%, and a net profit attributable to shareholders of 370 million yuan, up 1.87% year-on-year [1]. Group 2: Business Segments - The company's equipment sales were affected by industry changes, with 2024 equipment revenue reaching 8.44 billion yuan, a year-on-year decrease of 14.93% [2]. - The CT business line generated 3.048 billion yuan, down 25.03% year-on-year, while the MR business line brought in 3.192 billion yuan, a decrease of 2.66% [2]. - The maintenance service revenue grew to 1.356 billion yuan in 2024, reflecting a year-on-year increase of 26.8% [2]. Group 3: R&D and International Expansion - The company maintained strong R&D investment of 2.261 billion yuan in 2024, accounting for 21.95% of revenue [3]. - The company launched several strategic innovative products in 2024, including the uLinac HalosTx precision radiotherapy system and the uMR Max next-generation 3.0T MRI [3]. - International revenue reached 2.22 billion yuan in 2024, a year-on-year increase of 33.81%, representing 22.46% of total revenue [3]. Group 4: Profit Forecast and Valuation - The company is a leader in the domestic medical imaging equipment sector, with ongoing R&D and technological innovation enhancing its global competitiveness [3]. - The net profit forecasts for 2025 and 2026 have been revised down to 1.966 billion yuan and 2.281 billion yuan, respectively, reflecting reductions of 33.9% and 39.5% from previous estimates [3]. - A new net profit forecast for 2027 is set at 2.817 billion yuan, with a "buy" rating maintained due to increasing installation volumes and a structured product pipeline [3].

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Views - The company reported a revenue of 10.3 billion yuan in 2024, a year-over-year decrease of 9.73%, and a net profit attributable to shareholders of 1.262 billion yuan, down 36.09% year-over-year [2] - The company is actively expanding its overseas markets, having established sales networks in multiple countries, including the US, UK, Japan, and South Korea, with overseas revenue growing by 33.81% year-over-year to 2.22 billion yuan in 2024 [6][7] - The company has a strong focus on R&D, with an investment of 2.261 billion yuan in 2024, accounting for 21.95% of its revenue, and a patent application count exceeding 9,300 [7][8] Financial Performance Summary - In Q4 2024, the company achieved a revenue of 3.346 billion yuan, a decrease of 15.90% year-over-year, and a net profit of 591 million yuan, down 35.09% year-over-year [2] - For Q1 2025, the company reported a revenue of 2.478 billion yuan, an increase of 5.42% year-over-year, and a net profit of 370 million yuan, up 1.87% year-over-year [2] - The company expects revenues of 12.164 billion yuan, 14.488 billion yuan, and 17.612 billion yuan for 2025, 2026, and 2027 respectively, with corresponding net profits of 1.802 billion yuan, 2.408 billion yuan, and 3.259 billion yuan [9][11] Market Position and Competitive Advantage - The company is a leading domestic medical imaging equipment manufacturer with strong product competitiveness and high R&D barriers [9] - The company has achieved 100% self-research capability in core components across various business lines, including MR, CT, and MI, positioning itself as a global leader in technology [8][9]